Evidence map›Paper›PMID 27304883›Full record

ArticlePloS one2016

Putting PrEP into Practice: Lessons Learned from Early-Adopting U.S. Providers' Firsthand Experiences Providing HIV Pre-Exposure Prophylaxis and Associated Care.

Sarah K Calabrese, Manya Magnus, Kenneth H Mayer, Douglas S Krakower, Adam I Eldahan, Lauren A Gaston Hawkins, Nathan B Hansen, Trace S Kershaw, Kristen Underhill, Joseph R Betancourt and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 3 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Sarah K CalabreseDepartment of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, United States of America.
Manya MagnusDepartment of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC, United States of America.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, MA, United States of America.
Douglas S KrakowerThe Fenway Institute, Fenway Health, Boston, MA, United States of America.
Adam I EldahanDepartment of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, United States of America.
Lauren A Gaston HawkinsDepartment of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, United States of America.
Nathan B HansenCenter for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States of America.
Trace S KershawDepartment of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, United States of America.
Kristen UnderhillCenter for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States of America.
Joseph R BetancourtDisparities Solutions Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.
John F DovidioDepartment of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, United States of America.
Yale University · USBeth Israel Deaconess Medical Center · USFenway Health · USGeorge Washington University · USHarvard University · USUniversity of Georgia · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI John Edward Pachankis · 2001 to 2026
$48.5M
Optimizing HIV Pre-Exposure Prophylaxis through Shared Decision MakingK23MH098795 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KRAKOWER, DOUGLAS SCOTT · 2012 to 2016
$873k
PrEP for HIV Prevention in MSM: Mixed-Methods Study of Behavior & Message FramingK01MH093273 · NIMH · YALE UNIVERSITY · PI UNDERHILL, KRISTEN · 2011 to 2015
$873k
Intervention to Promote PrEP Awareness and Equitable Prescription among ProvidersK01MH103080 · NIMH · YALE UNIVERSITY · PI CALABRESE, SARAH K. · 2014 to 2017
$634k
NIAID NIH HHS P30 AI060354NIMHD NIH HHS L60 MD008519NIMH NIH HHS K01 MH093273NIMH NIH HHS K01 MH103080NIMH NIH HHS K23 MH098795NIMH NIH HHS P30 MH062294
6 · The paper itself

Abstract

Optimizing access to HIV pre-exposure prophylaxis (PrEP), an evidence-based HIV prevention resource, requires expanding healthcare providers' adoption of PrEP into clinical practice. This qualitative study explored PrEP providers' firsthand experiences relative to six commonly-cited barriers to prescription-financial coverage, implementation logistics, eligibility determination, adherence concerns, side effects, and anticipated behavior change (risk compensation)-as well as their recommendations for training PrEP-inexperienced providers. U.S.-based PrEP providers were recruited via direct outreach and referral from colleagues and other participants (2014-2015). One-on-one interviews were conducted in person or by phone, transcribed, and analyzed. The sample (n = 18) primarily practiced in the Northeastern (67%) or Southern (22%) U.S. Nearly all (94%) were medical doctors (MDs), most of whom self-identified as infectious disease specialists. Prior experience prescribing PrEP ranged from 2 to 325 patients. Overall, providers reported favorable experiences with PrEP implementation and indicated that commonly anticipated problems were minimal or manageable. PrEP was covered via insurance or other programs for most patients; however, pre-authorization requirements, laboratory/service provision costs, and high deductibles sometimes presented challenges. Various models of PrEP care and coordination with other providers were utilized, with several providers highlighting the value of clinical staff support. Eligibility was determined through joint decision-making with patients; CDC guidelines were commonly referenced but not considered absolute. Patient adherence was variable, with particularly strong adherence noted among patients who had actively sought PrEP (self-referred). Providers observed minimal adverse effects or increases in risk behavior. However, they identified several barriers with respect to accessing and engaging PrEP candidates. Providers offered a wide range of suggestions regarding content, strategy, and logistics surrounding PrEP training, highlighting sexual history-taking and sexual minority competence as areas to prioritize. These insights from early-adopting PrEP providers may facilitate adoption of PrEP into clinical practice by PrEP-inexperienced providers, thereby improving access for individuals at risk for HIV.

Indexed as

AdultAnti-HIV AgentsFemaleHealth PersonnelHIV InfectionsHumansMaleMiddle AgedPatient Acceptance of Health CarePre-Exposure ProphylaxisPreventive MedicineReproducibility of ResultsSurveys and QuestionnairesUnited StatesAnti-HIV Agents

Identifiers

PMID27304883
PMCPMC4909282
OpenAlexW2426840394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.